REGENXBIO is seeking to improve lives through the curative potential of gene therapy. Our NAV® Technology Platform has ushered in a new era of gene therapy innovation. We are leveraging our proprietary NAV Technology Platform to advance the development of potentially life-changing gene therapy treatments for retinal, metabolic and neurodegenerative diseases. Beyond our core therapeutic areas of focus, we are licensing our NAV Technology Platform to enable leading biotechnology companies to advance gene therapy programs for other serious diseases with unmet needs, such as spinal muscular atrophy, hemophilia, and Pompe disease.

NAV® Technology Licensees